How much retirees may save in 2026

Catherine Delahaye | Digitalvision | Getty Images
Top 10 drugs subject to new regulation Medicare price negotiations It goes into effect Jan. 1 and will provide significant out-of-pocket savings for some older Americans who rely on these medications.
Enrollees in Medicare Part D prescription drug plans could see their out-of-pocket costs for negotiated drugs fall by more than 50% on average in 2026. new research From AARP, a nonprofit organization representing Americans ages 50 and older.
Enrollees will be able to pay less than $100 a month for 7 out of 10 negotiated drugs next year, according to AARP research.
New Medicare Part D prescription drug price negotiations go into effect with the Inflation Reduction Act in 2022. Nearly 9 million Medicare Part D enrollees use the top 10 prescription drugs selected for price negotiations in 2026, according to AARP. Treatments are used for a variety of conditions, including autoimmune diseases, cancer, diabetes and heart disease.
In 2027, price reductions are planned for 15 more drug names under Medicare.
By 2026, Medicare drug price negotiations could save Medicare Part D enrollees $1.5 billion in out-of-pocket expenses, the Centers for Medicare and Medicaid Services estimates.
The Inflation Reduction Act requires Medicare to identify high-cost drugs and negotiate lower prices on behalf of beneficiaries and taxpayers who help fund the program, Nancy LeaMond, AARP’s director of advocacy and engagement, said in a Dec. 18 briefing on the study.
“We often talk about issues in terms of policy and data, but beyond the numbers, this is about the people in our lives, parents, grandparents, friends and neighbors, who will finally see relief from high drug costs and the fear that prices of needed drugs will spiral out of control,” LeaMond said. he said.
The Inflation Reduction Act also increases the annual Medicare Part D out-of-pocket spending cap to $2,100 per beneficiary in 2026 from the initial amount set under the law of $2,000 in 2025. Once out-of-pocket expenses for covered drugs reach this limit, the plan pays 100% for the remainder of the year. Other changes in the law include a $35-a-month cap on insulin for Medicare beneficiaries, discounts for beneficiaries if drug prices rise faster than inflation, and free vaccines to prevent certain conditions such as shingles.
The Trump administration is working separately to lower prescription drug prices for Americans through negotiations with nine major pharmaceutical companies. However, the “big beautiful” tax package signed in July made this so some medicines Eligibility for Medicare drug negotiations will either be delayed or excluded altogether.
How could costs for Medicare beneficiaries fall in 2026?
Overall, Medicare enrollees will see their costs for negotiated drugs fall by an average of 51%, AARP found, based on an analysis of changes in 56 individual plans between 2025 and 2026.
AARP found that in five states with high Medicare enrollment, enrollees’ cost sharing would decrease by an average of about 50% for 10 agreed-upon drugs.
Floridians are poised to see the largest decrease, averaging 54 percent, among the states included in the study. This is followed by Pennsylvania with 53%; California and New York each have 50%; and Texas, 48%.
Average monthly enrollee costs for 10 drugs are projected to decline from 2025 to 2026, according to AARP’s analysis of certain individual plans.
According to the study, the drug that could offer the biggest reduction in cost in dollar terms is Stelara, used to treat autoimmune disorders. Average monthly enrollee costs for this treatment could fall by $5,046, or 68%, in 2026, according to an analysis of data on AARP’s Medicare Plan Finder website.
Cancer treatment Imbruvica and Enbrel, a treatment for autoimmune diseases, are in the top three for most significant price reductions, potentially saving patients more than $1,000 per month.
AARP noted in its research that Medicare beneficiaries will benefit from the $2,100 out-of-pocket limit in 2026, although these three drugs still require high out-of-pocket expenses.
Here’s how much enrollees will pay and save, based on AARP’s analysis of available data:
Stelara
- Treatment: autoimmune conditions
- 2025 average monthly cost: $7,425
- 2026 average monthly cost: $2,379
- Potential savings: 68%
Imbruvica
- Treatment: cancer
- 2025 average monthly cost: $4,983
- 2026 average monthly cost: $2,813
- Potential savings: 44%
Enbrel
- Treatment: autoimmune conditions
- 2025 average monthly cost: $2,265
- 2026 average monthly cost: $619
- Potential savings: 73%
farxiga
- Treatment: Diabetes and heart disease
- 2025 average monthly cost: $141
- 2026 average monthly cost: $39
- Potential savings: 73%
jardiance
- Treatment: diabetes
- 2025 average monthly cost: $103
- 2026 average monthly cost: $43
- Potential savings: 58%
Eliquis
- Treatment: blood clots
- 2025 average monthly cost: $110
- 2026 average monthly cost: $51
- Potential savings: 53%
xarelto
- Treatment: blood clots
- 2025 average monthly cost: $103
- 2026 average monthly cost: $45
- Potential savings: 56%
Entrance
- Treatment: Chronic heart failure
- 2025 average monthly cost: $118
- 2026 average monthly cost: $64
- Potential savings: 46%
januvia
- Treatment: diabetes
- 2025 average monthly cost: $62
- 2026 average monthly cost: $27
- Potential savings: 57%
NovoLog
- Treatment: diabetes
- 2025 average monthly cost: $33
- 2026 average monthly cost: $27
- Potential savings: 16%
Of course, Medicare drug price reductions are based on AARP’s analysis of available data. Additional research is needed to evaluate the full effects of Medicare drug price negotiations, according to AARP. The organization notes that because the findings in its research are averages, differences may vary between individual plans.
Because individuals may see differences in drug price changes among available plans, AARP said it is still important to re-evaluate plan coverage each year.
People enrolled in private Medicare Advantage insurance plans may search for new coverage for a period of time. open enrollment The period from January 1 to March 31. All Medicare beneficiaries can choose to change coverage during annual open enrollment from October 15 to December 7. Other initial and special registration periods may apply depending on individual circumstances.


